Literature DB >> 25504047

OXPHOS dysfunction regulates integrin-β1 modifications and enhances cell motility and migration.

Joana B Nunes1, Joana Peixoto2, Paula Soares1, Valdemar Maximo1, Sandra Carvalho2, Salome S Pinho2, Andre F Vieira2, Joana Paredes1, Ana C Rego3, Ildete L Ferreira4, Maria Gomez-Lazaro5, Manuel Sobrinho-Simoes6, Keshav K Singh7, Jorge Lima8.   

Abstract

Mitochondria are central organelles for cellular metabolism. In cancer cells, mitochondrial oxidative phosphorylation (OXPHOS) dysfunction has been shown to promote migration, invasion, metastization and apoptosis resistance. With the purpose of analysing the effects of OXPHOS dysfunction in cancer cells and the molecular players involved, we generated cybrid cell lines harbouring either wild-type (WT) or mutant mitochondrial DNA (mtDNA) [tRNAmut cybrids, which harbour the pathogenic A3243T mutation in the leucine transfer RNA gene (tRNAleu)]. tRNAmut cybrids exhibited lower oxygen consumption and higher glucose consumption and lactate production than WT cybrids. tRNAmut cybrids displayed increased motility and migration capacities, which were associated with altered integrin-β1 N-glycosylation, in particular with higher levels of β-1,6-N-acetylglucosamine (GlcNAc) branched N-glycans. This integrin-β1 N-glycosylation pattern was correlated with higher levels of membrane-bound integrin-β1 and also with increased binding to fibronectin. When cultured in vitro, tRNAmut cybrids presented lower growth rate than WT cybrids, however, when injected in nude mice, tRNAmut cybrids produced larger tumours and showed higher metastatic potential than WT cybrids. We conclude that mtDNA-driven OXPHOS dysfunction correlates with increased motility and migration capacities, through a mechanism that may involve the cross talk between cancer cell mitochondria and the extracellular matrix.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25504047     DOI: 10.1093/hmg/ddu612

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  20 in total

Review 1.  From discovery of the CHOP axis and targeting ClpP to the identification of additional axes of the UPRmt driven by the estrogen receptor and SIRT3.

Authors:  Timothy C Kenny; Doris Germain
Journal:  J Bioenerg Biomembr       Date:  2017-08-10       Impact factor: 2.945

Review 2.  Mitohormesis, UPRmt, and the Complexity of Mitochondrial DNA Landscapes in Cancer.

Authors:  Timothy C Kenny; Maria L Gomez; Doris Germain
Journal:  Cancer Res       Date:  2019-09-04       Impact factor: 12.701

3.  Nitrogen Trapping as a Therapeutic Strategy in Tumors with Mitochondrial Dysfunction.

Authors:  Hanumantha Rao Madala; Iiro Taneli Helenius; Wen Zhou; Evanna Mills; Yiyun Zhang; Yan Liu; Ana M Metelo; Michelle L Kelley; Surendra Punganuru; Kyung Bo Kim; Benjamin Olenchock; Eugene Rhee; Andrew M Intlekofer; Othon Iliopoulos; Edward Chouchani; Jing-Ruey Joanna Yeh
Journal:  Cancer Res       Date:  2020-07-10       Impact factor: 12.701

Review 4.  Decoding Warburg's hypothesis: tumor-related mutations in the mitochondrial respiratory chain.

Authors:  Jose M Garcia-Heredia; Amancio Carnero
Journal:  Oncotarget       Date:  2015-12-08

5.  Integrin-FAK signaling rapidly and potently promotes mitochondrial function through STAT3.

Authors:  Nishant P Visavadiya; Matthew P Keasey; Vladislav Razskazovskiy; Kalpita Banerjee; Cuihong Jia; Chiharu Lovins; Gary L Wright; Theo Hagg
Journal:  Cell Commun Signal       Date:  2016-12-15       Impact factor: 5.712

Review 6.  Integrins and Cell Metabolism: An Intimate Relationship Impacting Cancer.

Authors:  Rehman Ata; Costin N Antonescu
Journal:  Int J Mol Sci       Date:  2017-01-18       Impact factor: 5.923

7.  Selected mitochondrial DNA landscapes activate the SIRT3 axis of the UPRmt to promote metastasis.

Authors:  T C Kenny; P Hart; M Ragazzi; M Sersinghe; J Chipuk; M A K Sagar; K W Eliceiri; T LaFramboise; S Grandhi; J Santos; A K Riar; L Papa; M D'Aurello; G Manfredi; M G Bonini; D Germain
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

Review 8.  Dynamin-Related Protein 1 at the Crossroads of Cancer.

Authors:  Ana Rita Lima; Liliana Santos; Marcelo Correia; Paula Soares; Manuel Sobrinho-Simões; Miguel Melo; Valdemar Máximo
Journal:  Genes (Basel)       Date:  2018-02-21       Impact factor: 4.096

Review 9.  The Mitochondrial Complex(I)ty of Cancer.

Authors:  Félix A Urra; Felipe Muñoz; Alenka Lovy; César Cárdenas
Journal:  Front Oncol       Date:  2017-06-08       Impact factor: 6.244

Review 10.  β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer.

Authors:  Anne-Florence Blandin; Guillaume Renner; Maxime Lehmann; Isabelle Lelong-Rebel; Sophie Martin; Monique Dontenwill
Journal:  Front Pharmacol       Date:  2015-11-24       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.